Fluzone High-dose Influenza Vaccine — Competitive Intelligence Brief

Fluzone High-dose Influenza Vaccine (Fluzone High-dose Influenza Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology.

phase 3 Inactivated influenza vaccine Immunology Biologic

Target snapshot

Fluzone High-dose Influenza Vaccine (Fluzone High-dose Influenza Vaccine) — University Health Network, Toronto. Fluzone High-dose stimulates a stronger immune response against influenza by delivering four times the standard antigen dose per strain, enhancing antibody production and cellular immunity in older adults.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluzone High-dose Influenza Vaccine TARGET	Fluzone High-dose Influenza Vaccine	University Health Network, Toronto	phase 3	Inactivated influenza vaccine
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Seasonal trivalent influenza vaccine, Fluarix	Seasonal trivalent influenza vaccine, Fluarix	Center for Disease Prevention and Control of Beijing Military Region	marketed	inactivated influenza vaccine
Fluzone® (IM)	Fluzone® (IM)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	inactivated influenza vaccine
SP Shz TIV	SP Shz TIV	Sanofi	marketed	Inactivated influenza vaccine
Influenza Fluzone vaccine	Influenza Fluzone vaccine	La Jolla Institute for Immunology	marketed	inactivated influenza vaccine
CSL Influenza Vaccine	CSL Influenza Vaccine	Seqirus	marketed	inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Seqirus · 5 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
4. Green Cross Corporation · 4 drugs in this class
5. Novartis · 2 drugs in this class
6. SK Chemicals Co., Ltd. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Hospital Israelita Albert Einstein · 2 drugs in this class
9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class